Expertise in nearly 40 psychiatric and neurological disorders, and clinically trained neuroscience teams led by scientists and clinicians with extensive neuroscience experience.
PPD's Phase I Clinic conducts clinical studies to determine how new medicines act in the bodies of healthy volunteers.
View all of PPD's news releases.
PPD Biotech is devoted to finding Phase I-IV clinical development solutions for biotech and small to midsize pharma companies. We know that every milestone, project update and change in direction you face is important. We provide a team of empowered, experienced and resourceful professionals who work as an extension of your team to get your treatments to the clinic faster.
We combine the global power and capabilities of PPD with the hands-on approach, dedication and innovative mindset that drive the success of biotech companies such as yours.
PPD Biotech shares the sense of urgency driving clients like Alnylam to deliver innovative therapies that will transform the lives of patients.
Motivated by an innovative biotech mindset that is selected for and cultivated within by our operational, medical and commercial teams
Empowered project teams with the ability to identify efficient pathways and the flexibility to scale up or down as your asset progresses
Executive leadership committed to the success of your projects
Rapid scalability, with the expertise of a strong global organization of approximately 23,000 professionals
Medical and regulatory expertise, as well as a wealth of data and analytics to provide superior guidance across the development spectrum
Full-service early phase through post-approval and laboratory drug development
Innovative Site and Patient Strategy
Allows Single-asset Biotech to Overcome Recruitment Challenges in a Breast Cancer Study
Tailored Partnership Approach and Expert Team
Drive Faster NDA Submission for a Biotech’s MS Program
Prioritization and Rapid Resource Mobilization
Speed Site Activation for Small Biotech Conducting a Global Phase III Prostate Cancer Study
Midsized Biotech Advances Asset Acquisition Strategy
Close Executive Engagement and Flexible Resource Planning
Global Head of PPD Biotech
Head of Biotech Operations
Head of Commercial
We understand your sense of urgency and value the need for a transparent partnership with a shared mindset. We are ready to partner with you to drive your innovative new therapies forward.
To request a proposal or to contact a business development representative regarding PPD Biotech services, please complete the form below. Fields marked with * are required.
We want to hear from you
Register in PPD's Database
Anshul Thakral, MBA, serves as senior vice president and global head of PPD® Biotech. He joined PPD’s executive team in 2016 to lead the company’s biotech customer segment with more than 16 years of experience in the pharmaceutical and biotechnology industries as a general manager, management consultant and entrepreneur.
Since joining, Mr. Thakral has been instrumental in further refining and delivering on PPD Biotech’s mission of providing a tailored operational model that meets the unique needs of biotech and small to midsized pharma. Prior to PPD Biotech, Mr. Thakral ran the global life sciences business unit at Gerson Lehrman Group (GLG), where he created a customer business model to serve the pharmaceutical and biotechnology industries. Mr. Thakral also worked at McKinsey & Company as an associate principal in the health care practice, counseling senior management and CEOs of global pharmaceutical and biotechnology companies on critical topics including growth, strategy, R&D, business development, go-to-market approach and commercial models.
Mr. Thakral received his undergraduate and master’s degrees in biomedical engineering from Johns Hopkins University and earned an MBA from the Wharton School at the University of Pennsylvania. Mr. Thakral is also a co-founder and board member of the Newark Mentoring Movement..
Elisha Talley-Roithner is the head of biotech operations. Applying more than 20 years of clinical research experience, including more than 15 years of project management experience, Ms. Talley-Roithner is responsible for PPD® Biotech’s global operations and aligning execution and resourcing strategy with the needs of our clients. She is also responsible for monitoring and evaluating the progress of PPD Biotech programs to ensure studies are consistently delivered on target. Prior to this role, she served as the global therapeutic head for infectious and respiratory diseases at PPD.
Elisha is a fierce advocate for her clients and project teams, and she is committed to high-quality delivery across PPD Biotech’s portfolio of work.
Daniel Burch, M.D., MBA, is the global medical officer for PPD® Biotech, where he oversees medical and product development strategy for our clients.
Dr. Burch joined PPD in 2012 and led the company’s global neuroscience product development group. Before taking the role, Dr. Burch served as executive vice president and chief medical officer at CeNeRx BioPharma, a venture-backed clinical-stage biotech, where he managed a portfolio of medicines focused on neuropsychiatric diseases. Prior to that, he headed the Neuroscience Medicines Development Centre at GlaxoSmithKline with global responsibility for Phase II through lifecycle management. Having worked for more than 20 years in many aspects of medicines development and more than 10 years in neuropsychiatric drug development, his personal goal is to promote and facilitate the development of medicines in areas of highest unmet need.
Dr. Burch earned his medical degree from the Vanderbilt University School of Medicine, where he completed a residency in internal medicine. Subsequently, he completed a fellowship and postdoctoral research in infectious diseases at the Washington University School of Medicine. He earned his MBA at the Wharton School the University of Pennsylvania. He serves on the Institute of Medicine Forum on Neuroscience and Nervous System Disorders.
Shields Carstarphen is head of commercial for PPD® Biotech. Much of Ms. Carstarphen’s career has been focused on understanding and meeting the needs of the biotech market. She brings significant experience in building customized commercial models and partnership strategies, which leverage the breadth of PPD’s global infrastructure. Ms. Carstarphen has an outstanding track record of success across all customer segments in the organization. In addition to her reputation with our customers, she is also known as a driver of and an active participant in process improvement initiatives to establish best practices and maximize productivity.
In her previous role at PPD, Ms. Carstarphen led several global teams within PPD’s commercial organization to build best-in-class partnerships and solutions to critical business needs, including developing governance structures, utilizing performance measures to drive desired partnership behaviors and leading or actively participating in governance committees. She held business development positions at Rho and Medifacts before joining PPD in 2006.
© 2020 PPD, Inc. All Rights Reserved.